Generali Investments CEE investicni spolecnost a.s. Grows Stock Holdings in Colgate-Palmolive Company $CL

Generali Investments CEE investicni spolecnost a.s. grew its holdings in Colgate-Palmolive Company (NYSE:CL) by 100.6% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 52,948 shares of the company’s stock after buying an additional 26,548 shares during the period. Generali Investments CEE investicni spolecnost a.s.’s holdings in Colgate-Palmolive were worth $4,184,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also recently made changes to their positions in the company. Norges Bank purchased a new position in Colgate-Palmolive in the second quarter worth about $960,390,000. Invesco Ltd. raised its position in Colgate-Palmolive by 13.1% during the third quarter. Invesco Ltd. now owns 8,467,993 shares of the company’s stock valued at $676,931,000 after purchasing an additional 978,943 shares during the period. Diamond Hill Capital Management Inc. lifted its stake in shares of Colgate-Palmolive by 46.7% in the 3rd quarter. Diamond Hill Capital Management Inc. now owns 8,077,549 shares of the company’s stock valued at $645,719,000 after purchasing an additional 2,572,796 shares during the last quarter. Ameriprise Financial Inc. lifted its stake in shares of Colgate-Palmolive by 5.1% in the 3rd quarter. Ameriprise Financial Inc. now owns 6,423,764 shares of the company’s stock valued at $517,167,000 after purchasing an additional 314,584 shares during the last quarter. Finally, Amundi boosted its holdings in shares of Colgate-Palmolive by 41.6% in the 3rd quarter. Amundi now owns 6,294,445 shares of the company’s stock worth $487,505,000 after purchasing an additional 1,850,412 shares during the period. 80.41% of the stock is currently owned by institutional investors.

Insider Activity at Colgate-Palmolive

In related news, CFO Stanley J. Sutula III sold 97,843 shares of the firm’s stock in a transaction dated Wednesday, February 4th. The shares were sold at an average price of $94.27, for a total value of $9,223,659.61. Following the transaction, the chief financial officer owned 55,310 shares of the company’s stock, valued at $5,214,073.70. This trade represents a 63.89% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider John Hazlin sold 20,989 shares of Colgate-Palmolive stock in a transaction dated Tuesday, February 10th. The shares were sold at an average price of $94.25, for a total transaction of $1,978,213.25. Following the sale, the insider owned 17,645 shares of the company’s stock, valued at $1,663,041.25. The trade was a 54.33% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders sold 184,683 shares of company stock worth $17,486,693. 0.34% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on CL. Piper Sandler boosted their target price on Colgate-Palmolive from $88.00 to $96.00 and gave the company an “overweight” rating in a research report on Friday, January 30th. Citigroup lifted their price objective on shares of Colgate-Palmolive from $95.00 to $105.00 and gave the stock a “buy” rating in a research note on Monday, February 2nd. Morgan Stanley boosted their price objective on shares of Colgate-Palmolive from $87.00 to $100.00 and gave the company an “overweight” rating in a research report on Monday, February 2nd. Wells Fargo & Company increased their target price on shares of Colgate-Palmolive from $86.00 to $94.00 and gave the company an “equal weight” rating in a research note on Sunday, February 1st. Finally, Barclays raised their target price on shares of Colgate-Palmolive from $83.00 to $88.00 and gave the stock an “equal weight” rating in a report on Tuesday, February 3rd. Eleven investment analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $94.75.

Colgate-Palmolive Price Performance

Shares of CL stock opened at $84.25 on Friday. The stock has a 50 day moving average price of $91.11 and a 200 day moving average price of $83.38. Colgate-Palmolive Company has a 52-week low of $74.54 and a 52-week high of $99.33. The company has a debt-to-equity ratio of 18.82, a quick ratio of 0.54 and a current ratio of 0.83. The firm has a market capitalization of $67.59 billion, a P/E ratio of 32.16, a P/E/G ratio of 3.77 and a beta of 0.28.

Colgate-Palmolive (NYSE:CL) last announced its quarterly earnings data on Friday, January 30th. The company reported $0.95 EPS for the quarter, beating the consensus estimate of $0.91 by $0.04. Colgate-Palmolive had a return on equity of 353.72% and a net margin of 10.45%.The company had revenue of $5.23 billion for the quarter, compared to the consensus estimate of $5.13 billion. During the same quarter in the prior year, the company posted $0.91 EPS. Colgate-Palmolive’s quarterly revenue was up 5.8% on a year-over-year basis. As a group, sell-side analysts predict that Colgate-Palmolive Company will post 3.75 earnings per share for the current year.

Colgate-Palmolive Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, May 15th. Stockholders of record on Monday, April 20th will be issued a $0.53 dividend. The ex-dividend date is Monday, April 20th. This is a boost from Colgate-Palmolive’s previous quarterly dividend of $0.52. This represents a $2.12 dividend on an annualized basis and a dividend yield of 2.5%. Colgate-Palmolive’s dividend payout ratio (DPR) is currently 79.39%.

Colgate-Palmolive Profile

Colgate-Palmolive Company is a global consumer products company with a long history in household and personal care categories. The business traces its roots to the early 19th century and has evolved into a multinational manufacturer and marketer of everyday consumer goods focused on health, hygiene and home care.

The company’s core activities center on oral care, personal care, home care and pet nutrition. Its product portfolio includes toothpaste, toothbrushes and mouthwash in oral care; soaps, body washes and deodorants in personal care; dishwashing liquids, surface cleaners and other household products in home care; and scientifically formulated pet foods under its pet nutrition business.